Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $30.43 USD
Change Today +0.212 / 0.70%
Volume 33.3K
OFIX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 9:44 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

orthofix international nv (OFIX) Snapshot

Open
$30.14
Previous Close
$30.52
Day High
$30.54
Day Low
$30.14
52 Week High
07/2/14 - $36.90
52 Week Low
03/27/14 - $26.58
Market Cap
555.7M
Average Volume 10 Days
110.2K
EPS TTM
$0.16
Shares Outstanding
18.4M
EX-Date
--
P/E TM
192.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for ORTHOFIX INTERNATIONAL NV (OFIX)

orthofix international nv (OFIX) Related Businessweek News

No Related Businessweek News Found

orthofix international nv (OFIX) Details

Orthofix International N.V., a medical device company, designs, develops, manufactures, markets, and distributes medical devices used principally by musculoskeletal medical specialists for spine and orthopedic applications. The company operates in four segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation. The BioStim segment offers a range of devices for use as adjunctive treatment to enhance fusion success in cervical and lumbar spine fusion, as well as a therapeutic treatment for non-healing fractures outside of the spine. The Biologics segment provides a portfolio of regenerative products that allow physicians to treat a range of spinal and orthopedic conditions under the Trinity Evolution and Trinity Elite names. The Extremity Fixation segment offers orthopedic products used in fracture repair, deformity correction, and bone reconstruction. The Spine Fixation segment provides a range of implant products used in surgical procedures of the spine. The company markets and distributes its products directly to hospitals, doctors, and other healthcare providers in the United States, the United Kingdom, Italy, Germany, Switzerland, Austria, France, Belgium, Brazil, Australia, and Puerto Rico, as well as through independent distributors, sales representatives, and affiliates in other markets. Orthofix International N.V. was founded in 1987 and is headquartered in Willemstad, Curaçao.

889 Employees
Last Reported Date: 03/31/14
Founded in 1987

orthofix international nv (OFIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $452.8K
President of Global Extremity Fixation
Total Annual Compensation: $437.2K
Chief Strategy Officer
Total Annual Compensation: $460.0K
Chief Administrative Officer, General Counsel...
Total Annual Compensation: $455.0K
Compensation as of Fiscal Year 2013.

orthofix international nv (OFIX) Key Developments

Orthofix International N.V. Receives Additional Non-Compliance Notice

On March 18, 2015, Orthofix International N.V. received an anticipated letter from NASDAQ noting that the 2014 Annual Report on Form 10-K had not been filed by its due date with the SEC on March 16, 2015 and, as such, represented an additional basis for non-compliance with Listing Rule 5250(c)(1). The company continues to work to complete the procedures needed to file its two delayed quarterly reports and the amended reports containing its restatement for prior periods, as well as its 2014 Annual Report on Form 10-K. As requested by the letter from NASDAQ, the company will be providing a written update to the Hearings Panel regarding these matters on or before March 25, 2015.

Orthofix International N.V. announced delayed annual 10-K filing

On 03/17/2015, Orthofix International N.V. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

NASDAQ Hearing Panel Grants Additional Time To Orthofix International To Complete The Late Reports And The Further Restatement

As previously disclosed, Orthofix International N.V. recently requested an additional extension from a Nasdaq Hearings Panel (Hearings Panel) to permit additional time for the Company to complete the Late Reports and the Further Restatement. On January 15, 2015, the Company received notice from NASDAQ’s Office of General Counsel that the Hearings Panel has granted the Company continued listing through March 31, 2015, conditioned upon the Company being current in its filing obligations with the Securities and Exchange Commission (the “SEC”) as of such date (including by having filed with the SEC on or prior to such date the Late Reports and the amended reports containing the Further Restatement).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OFIX:US $30.43 USD +0.212

OFIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $17.75 USD +0.19
Exactech Inc $25.24 USD +0.20
Merit Medical Systems Inc $18.58 USD -0.04
NxStage Medical Inc $17.06 USD +0.22
RTI Surgical Inc $5.07 USD +0.02
View Industry Companies
 

Industry Analysis

OFIX

Industry Average

Valuation OFIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORTHOFIX INTERNATIONAL NV, please visit www.orthofix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.